GESTIÓN EN SALUD PÚBLICA: Studies Using Leftover, Deidentified Human Specimens Require IRB Review – Letter to Industry | FDA

martes, 19 de octubre de 2021

Studies Using Leftover, Deidentified Human Specimens Require IRB Review – Letter to Industry | FDA

Studies Using Leftover, Deidentified Human Specimens Require IRB Review – Letter to Industry | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)